Gastric MALT lymphoma, intractable peptic ulcer NHPH infection, gastric MALT, refractory peptic ulcer.
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients with H.pylori negative gastric MALT lymphoma who are able to observe the lesion endoscopically Patients with H.pylori-negative or non-NSAIDs confirmed gastric or duodenal ulcer after eradication 1) Patients (both male and female) over the age of 18 2) Patients who have obtained written consent and their surrogates (if they are minors, consent is obtained from the surrogate) 3) Patients diagnosed with gastric MALT lymphoma or gastric or duodenal ulcer 4) Patients who are H.pylori negative or after successful H.pylori eradication treatment (5) Whether inpatient or outpatient
Exclusion criteria
Exclusion criteria: 1) Patients who could not give consent 2) Patients with poorly controlled complications Patients with advanced stages of cancer Patients with acute or unstable underlying disease 3) Pregnant or lactating women 4) Patients taking drugs with a high rate of drug interactions expected to occur during treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Success or failure of NHPH include H.suis sterilization and the efficacy of eradication of disease | — |
Secondary
| Measure | Time frame |
|---|---|
| Identify the most recommended method of H.suis sterilization Verification of which H.suis infection diagnostics are useful in determining the success of eradication 1. gastric MALT lymphoma patients and gastric/duodenal ulcer patients after H.pylori-negative or H.pylori eradication treatment NHPH infection rate including H.suis 2. incidence of adverse events due to NHPH eradication, including H.suis 3. evaluation of drugs for the treatment of NHPH infection, including H.suis 4. evaluation of diagnostic methods for NHPH infection, including H.suis | — |
Contacts
Tokai University School of Medicine